Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Our commitment is to make every effort to support patients in need of treatment options.
Atara will consider providing an individual patient with access to investigational product candidate tab-cel® through an expanded access study. A treating physician may request information about how to apply for access to one of Atara’s investigational product candidates by contacting Atara. Atara will use reasonable efforts to respond and acknowledge each request within one (1) business day of submission. All physicians who receive Atara’s investigational product candidate are required to comply with all applicable laws and regulations, and contractual conditions, including those relating to safety reporting.
Atara will use the following criteria to review each request:
Each request will be evaluated individually to assess the above criteria.
Additional information about existing expanded access study protocols for Atara’s investigational product candidates can be found at the following links:
Atara tab‐cel® (tabelecleucel; formerly known as ATA129): NCT02822495